They also showed that signaling patterns are distinct in some BRAFV600E cancers, and that there are communalities with BRAF wildtype melanomas, which collectively confirmed that BRAF genomic status might be insufficient in assigning therapy. The gene discussed is BRAF; the disease is melanoma.